Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.

@article{Brem2011DistinctCA,
  title={Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.},
  author={Elizabeth A Brem and Karen Thudium and Sapna Khubchandani and Ping-Chiao Tsai and Scott H Olejniczak and Seema Ali Bhat and Wasif Riaz and Jenny X Gu and Arshad Iqbal and Ryan Campagna and Joy Knight and Cory Mavis and Paul W. O. Hoskin and George Michael Deeb and John F Gibbs and Gerald J. Fetterly and Myron S. Czuczman and Francisco J Hernandez-Ilizaliturri},
  journal={British journal of haematology},
  year={2011},
  volume={153 5},
  pages={599-611}
}
Bcl-2 proteins represent a rheostat that controls cellular viability. Obatoclax, a BH3-mimetic, has been designed to specifically target and counteract anti-apoptotic Bcl-2 proteins. We evaluated the biological effects of obatoclax on the anti-tumour activity of rituximab and chemotherapy agents. Obatoclax induced cell death of rituximab/chemotherapy-sensitive (RSCL), -resistant cell lines (RRCL) and primary tumour-cells derived from patients with B-cell lymphomas (N=39). Obatoclax also… CONTINUE READING

From This Paper

Topics from this paper.
19 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…